On January 30, UBS reaffirmed its Buy recommendation on Walmart, citing the retailer’s resilient fundamentals and growth initiatives. The firm increased its 12-month price objective by more than 10%, reflecting confidence in Walmart’s ability to leverage its scale and invest in high-return areas. UBS highlighted the company’s consistent market share gains and efficient cost management as key factors underpinning its positive outlook.

Walmart reported $681 billion in revenue for fiscal 2025, equivalent to nearly $1.9 billion per day, and achieved a 4.3 percent operating margin—up from 3.3 percent two years earlier. Operating income reached $29.3 billion, driven by higher-margin offerings in pharmacy services, digital advertising, and supply-chain efficiencies. Analysts note that each tenth of a percentage point in margin expansion adds roughly $680 million to operating profit, underscoring the significance of Walmart’s ongoing productivity initiatives.

On February 1, John Furner will assume the role of CEO of Walmart Inc., succeeding Doug McMillon. Furner’s background leading Walmart U.S. and his reputation as a technology advocate—evident in early drone tests and AI pilots—suggest a renewed emphasis on digital innovation. His promotion coincides with a year-over-year share gain of 20 percent and positions the company to accelerate e-commerce integration and data-driven personalization across its omnichannel platform.

Walmart unveiled an expansion of its pharmacy workforce by creating 3,000 new team-lead positions and increasing pay ranges for technicians, with top-certified roles now earning up to $40.50 per hour. The move aims to free pharmacists for patient care and support the rollout of clinical research sites in select locations this spring. By deepening its healthcare offerings—pharmacy, immunizations and in-store clinics—Walmart seeks to drive more frequent store visits and capture a larger share of consumers’ out-of-pocket health spending.